Edgar Filing: Evoke Pharma Inc - Form 4

Evoke Pharma Form 4	Inc										
May 22, 2014	4							-	APPROVAL		
	• UNITED	STATES					E COMMISSION	NOMB	3235-0287		
Check this b if no longer subject to Section 16. Form 4 or Form 5 obligations may continu <i>See</i> Instructi	 STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 							Expires: Estimated burden ho response.	urs per		
1(b).											
(Print or Type Res	ponses)										
1. Name and Adda WIDDER KEN		Person <u>*</u>	Symbol	er Name and Pharma Ir		-	5. Relationship o Issuer	of Reporting Pe	rson(s) to		
(Last)	(First) (Middle)		of Earliest T	-	z]	(Che	eck all applicab	k all applicable)		
C/O EVOKE F LOMAS SAN SUITE 270	PHARMA, IN	C., 505		Day/Year)	luisuetton		X Director Officer (giv below)		0% Owner her (specify		
SOLANA BEA	(Street) ACH, CA 920	75		endment, Day/Yea	-	I	6. Individual or . Applicable Line) _X_ Form filed by Form filed by Person		Person		
(City)	(State)	(Zip)	Tab	ole I - Non-I	Derivative	Securities A	Acquired, Disposed	of, or Beneficia	ally Owned		
	Transaction Date onth/Day/Year)	2A. Deem Execution any (Month/Da	Date, if	Code	4. Securiti nAcquired Disposed (Instr. 3, 4 Amount	(A) or of (D)	5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)		
Reminder: Report	on a separate line	e for each cl	ass of sec	urities benef	-	-	-				
					inform requir	ation cont ed to resp ys a curre	spond to the colle tained in this form ond unless the fo ntly valid OMB co	n are not rm	SEC 1474 (9-02)		
	Tab			curities Acq ls, warrants			Beneficially Owned securities)	I			
1. Title of 2.	3. Trans	saction Date	e 3A. Dee	emed	4.	5. Number	6. Date Exercisa	ible and 7	7. Title and Amoun		

1. Title of	2.	3. Transaction Date	3A. Deemed	4. 5. Number	6. Date Exercisable and	7. Title and Amount of	8. I
Derivative	Conversion	(Month/Day/Year)	Execution Date, if	Transaction f Derivative	Expiration Date	Underlying Securities	Der

Edgar Filing: Evoke Pharma Inc - Form 4

Security (Instr. 3)	or Exercise Price of Derivative Security		any (Month/Day/Year)	Code (Instr. 8	 A (A D (I (I 	Securities (Month/Day/ Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5)		/Year)	(Instr. 3 and 4)		Sec (In	
				Code V	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	
Stock Option (Right to Buy)	\$ 7.2	05/20/2014		А	9	9,000		(1)	05/19/2024	Common Stock	9,000	

Reporting Owners

Reporting Owner Name / Address	Relationships						
FB	Director	10% Owner	Officer	Other			
WIDDER KENNETH J C/O EVOKE PHARMA, INC. 505 LOMAS SANTA FE DRIVE, SUITE 270 SOLANA BEACH, CA 92075	Х	Х					
Signatures							
/s/ Matthew J. D'Onofrio, Attorney-in-fact for K Widder	05/22/2	2014					
** Signature of Reporting Person			Date				

Explanation of Responses:

* If the form is filed by more than one reporting person, *see* Instruction 4(b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

(1) The total number of shares of common stock subject to the option vests on the one-year anniversary of the date of grant (5/20/2014), subject to the reporting person's continued service to the Issuer through such vesting date.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.